Regeneron Pharmaceuticals (REGN) Depreciation & Amortization (CF) (2009 - 2026)

Regeneron Pharmaceuticals has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $123.2 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 2.92% year-over-year to $123.2 million; the trailing twelve-month figure through Mar 2026 stood at $540.0 million (up 8.94% YoY), and the FY2025 full-year result was $543.7 million, up 12.59% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $123.2 million, down from $145.0 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $145.0 million in Q4 2025, with the low at $74.3 million in Q1 2022.
• Average Depreciation & Amortization (CF) over 5 years is $112.5 million, with a median of $114.1 million recorded in 2024.
• Year-over-year, Depreciation & Amortization (CF) surged 38.58% in 2023 and retreated 2.92% in 2026.
• Tracing REGN's Depreciation & Amortization (CF) over 5 years: stood at $100.1 million in 2022, then gained by 12.89% to $113.0 million in 2023, then rose by 11.86% to $126.4 million in 2024, then rose by 14.72% to $145.0 million in 2025, then retreated by 15.03% to $123.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $123.2 million (Q1 2026), $145.0 million (Q4 2025), and $136.7 million (Q3 2025), per Business Quant data.

Peer Comparison